{"text": ["AbbVie", "Buys", "Rights", "to", "Novel", "Immunotherapy", "for", "Multiple", "Myeloma"], "created_at": "2019-02-12 16:49:22"}
{"text": ["AbbVie", "Buys", "Rights", "to", "Novel", "Immunotherapy", "for", "Multiple", "Myeloma"], "created_at": "2019-02-12 16:49:22"}
{"text": ["Better", "Buy:", "Gilead", "Sciences", "vs.", "Pfizer"], "created_at": "2019-02-12 14:38:35"}
{"text": ["Better", "Buy:", "Gilead", "Sciences", "vs.", "Pfizer"], "created_at": "2019-02-12 14:38:35"}
{"text": ["AbbVie", "Buys", "Rights", "to", "Novel", "Immunotherapy", "for", "Multiple", "Myeloma"], "created_at": "2019-02-12 14:11:02"}
{"text": ["5", "Aristocrats", "for", "Stable", "Income"], "created_at": "2019-02-12 10:00:00"}
{"text": ["5", "High-Growth", "Stocks", "Undervalued", "by", "the", "Market"], "created_at": "2019-02-12 00:35:47"}
{"text": ["5", "High-Growth", "Stocks", "Undervalued", "by", "the", "Market"], "created_at": "2019-02-12 00:35:47"}
